The FDA told Fortune in a statement that it’s a pilot program which “advances the Commissioner’s goal of improving efficiency while fully maintaining FDA’s rigorous scientific standards and requirements.” The program intends to reward review staff “for efficiency and excellence,” but it won’t change review criteria, evidentiary thresholds, or quality safeguards.
ВсеОбществоПолитикаПроисшествияРегионыМосква69-я параллельМоя страна，推荐阅读体育直播获取更多信息
Follow topics & set alerts with myFT。业内人士推荐体育直播作为进阶阅读
Материалы по теме: